Erbitux® is indicated for the treatment of patients with epidermal growth factor receptor (EGFR) - expressing, RAS wild-type metastatic colorectal cancer• In combination with irinotecan-based chemotherapy• In first-line in combination with FOLFOX• as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecanErbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck (SCCHN)• in combination with radiation therapy for locally advanced disease• in combination with platinum-based chemotherapy for recurrent and/or metastatic disease• as a single agent after failure of platinum-based chemotherapy for recurrent and/or metastatic disease